110 related articles for article (PubMed ID: 8040124)
1. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies.
Caillot D; Reny G; Solary E; Casasnovas O; Chavanet P; Bonnotte B; Perello L; Dumas M; Entezam F; Guy H
J Antimicrob Chemother; 1994 Mar; 33(3):603-13. PubMed ID: 8040124
[TBL] [Abstract][Full Text] [Related]
2. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients.
Moreau P; Milpied N; Fayette N; Ramée JF; Harousseau JL
J Antimicrob Chemother; 1992 Oct; 30(4):535-41. PubMed ID: 1490923
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients.
Nucci M; Loureiro M; Silveira F; Casali AR; Bouzas LF; Velasco E; Spector N; Pulcheri W
Antimicrob Agents Chemother; 1999 Jun; 43(6):1445-8. PubMed ID: 10348768
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis.
Joly V; Aubry P; Ndayiragide A; Carrière I; Kawa E; Mlika-Cabanne N; Aboulker JP; Coulaud JP; Larouze B; Yeni P
Clin Infect Dis; 1996 Sep; 23(3):556-62. PubMed ID: 8879780
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Intralipid infusion in reducing amphotericin-B-associated nephrotoxicity in head and neck invasive fungal infection: A randomized, controlled trial.
Hasibi M; Jafari S; Manshadi SA; Asadollahi M; Salehi M; Zarch VV; Kouhi A
Ear Nose Throat J; 2017 Feb; 96(2):E18-E22. PubMed ID: 28231371
[TBL] [Abstract][Full Text] [Related]
6. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion.
Nath CE; Shaw PJ; Gunning R; McLachlan AJ; Earl JW
Antimicrob Agents Chemother; 1999 Jun; 43(6):1417-23. PubMed ID: 10348763
[TBL] [Abstract][Full Text] [Related]
7. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.
Pascual B; Ayestaran A; Montoro JB; Oliveras J; Estibalez A; Julia A; Lopez A
Ann Pharmacother; 1995 Dec; 29(12):1197-201. PubMed ID: 8672820
[TBL] [Abstract][Full Text] [Related]
8. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
Schöffski P; Freund M; Wunder R; Petersen D; Köhne CH; Hecker H; Schubert U; Ganser A
BMJ; 1998 Aug; 317(7155):379-84. PubMed ID: 9694753
[TBL] [Abstract][Full Text] [Related]
9. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients.
Sorkine P; Nagar H; Weinbroum A; Setton A; Israitel E; Scarlatt A; Silbiger A; Rudick V; Kluger Y; Halpern P
Crit Care Med; 1996 Aug; 24(8):1311-5. PubMed ID: 8706484
[TBL] [Abstract][Full Text] [Related]
10. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?].
Hernández G; Altermatt F; Bernucci F; Acuña D; Apablaza F; Valenzuela F; Lefio A; Pérez C; Bugedo G; Castillo L
Rev Med Chil; 2000 Oct; 128(10):1101-7. PubMed ID: 11349508
[TBL] [Abstract][Full Text] [Related]
11. In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits.
Chavanet P; Duong M; Buisson M; Hamel H; Dubois C; Bonnin A; Portier H
J Antimicrob Chemother; 1997 Mar; 39(3):427-30. PubMed ID: 9096196
[TBL] [Abstract][Full Text] [Related]
12. A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients.
Barquist E; Fein E; Shadick D; Johnson J; Clark J; Shatz D
J Trauma; 1999 Aug; 47(2):336-40. PubMed ID: 10452470
[TBL] [Abstract][Full Text] [Related]
13. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
Chavanet PY; Garry I; Charlier N; Caillot D; Kisterman JP; D'Athis M; Portier H
BMJ; 1992 Oct; 305(6859):921-5. PubMed ID: 1458072
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients.
Caillot D; Casasnovas O; Solary E; Chavanet P; Bonnotte B; Reny G; Entezam F; Lopez J; Bonnin A; Guy H
J Antimicrob Chemother; 1993 Jan; 31(1):161-9. PubMed ID: 8444659
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.
Ayestarán A; López RM; Montoro JB; Estíbalez A; Pou L; Julià A; López A; Pascual B
Antimicrob Agents Chemother; 1996 Mar; 40(3):609-12. PubMed ID: 8851579
[TBL] [Abstract][Full Text] [Related]
16. Nephrotoxicity of amphotericin B administered to dogs in a fat emulsion versus five percent dextrose solution.
Randall SR; Adams LG; White MR; DeNicola DB
Am J Vet Res; 1996 Jul; 57(7):1054-8. PubMed ID: 8807021
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients.
Joly V; Geoffray C; Reynes J; Goujard C; Méchali D; Maslo C; Raffi F; Yeni P
J Antimicrob Chemother; 1996 Jul; 38(1):117-26. PubMed ID: 8858463
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B toxicity reduced by administration in fat emulsion.
Anderson RP; Clark DA
Ann Pharmacother; 1995 May; 29(5):496-500. PubMed ID: 7655134
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B.
Caillot D; Chavanet P; Casasnovas O; Solary E; Zanetta G; Buisson M; Wagner O; Cuisenier B; Bonnin A; Camerlynck P
Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):722-5. PubMed ID: 1425731
[TBL] [Abstract][Full Text] [Related]
20. Effect of salt supplementation on amphotericin B nephrotoxicity.
Llanos A; Cieza J; Bernardo J; Echevarria J; Biaggioni I; Sabra R; Branch RA
Kidney Int; 1991 Aug; 40(2):302-8. PubMed ID: 1942779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]